Roche Sees Biomarker Data As Support For Immuno-Oncology Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Use of PD-L1 expression as a biomarker may be up for debate at ASCO, but Roche assures analysts that proper application will unlock its combination-heavy development strategy.